Acumen Pharmaceuticals to Host Virtual R&D Day on Oct. 2, 2024
September 25, 2024 16:00 ET
|
Acumen Pharmaceuticals, Inc.
NEWTON, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic...
FLUX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Flux Power Holdings, Inc. and Encourages Investors to Contact the Firm!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flux Power Holdings, Inc....
NFE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that New Fortress Energy Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
FULC INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Fulcrum Therapeutics, Inc. and Encourages Investors to Contact the Firm!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Fulcrum Therapeutics, Inc....
EXTR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Extreme Networks, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
FIVE INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Five Below, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
PDD INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that PDD Holdings Inc. f/k/a Pinduoduo Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
MEI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Methode Electronics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
SYM INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Symbotic, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
September 25, 2024 16:00 ET
|
Bronstein, Gewirtz & Grossman, LLC
NEW YORK, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been...
Inventiva provides a corporate update and reports its unaudited 2024 first-half financial results
September 25, 2024 16:00 ET
|
INVENTIVA
Recruitment in NATiV3 clinical trial progresses with over 85% of the targeted number of patients enrolled in the main cohort and a statistical powering of the study expected to be superior to 95% for...